@article{2b98f6123303412da3e49204d0eba239,
title = "Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study",
abstract = "To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).",
keywords = "Adenocarcinoma, Administration, Metronomic, Aged, Aged, 80 and over, Chemoradiation, Chemoradiotherapy, Disease-Free Survival, Dose Fractionation, Humans, Kaplan-Meier Estimate, Male, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, hormone-refractory prostate cancer, metronomic chemotherapy, phase I study, Adenocarcinoma, Administration, Metronomic, Aged, Aged, 80 and over, Chemoradiation, Chemoradiotherapy, Disease-Free Survival, Dose Fractionation, Humans, Kaplan-Meier Estimate, Male, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, hormone-refractory prostate cancer, metronomic chemotherapy, phase I study",
author = "Morganti, {Alessio Giuseppe} and Mariangela Massaccesi and Luciana Caravatta and Gabriella Macchia and Vincenzo Picardi and Francesco Deodato and Edy Ippolito and Samantha Mignogna and Milena Ferro and Savino Cilla and Mattiucci, {Gian Carlo} and Vincenzo Valentini",
year = "2013",
language = "English",
volume = "33",
pages = "4585--4589",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL:
[email protected], INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945",
}
